- Record: found
- Abstract: found
- Article: not found
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Karim Fizazi
1 ,
Howard I Scher ,
Arturo Molina ,
Christopher J Logothetis ,
Kim N Chi ,
Robert J Jones ,
John N Staffurth ,
Scott North ,
Nicholas J Vogelzang ,
Fred Saad ,
Paul Mainwaring ,
Stephen Harland ,
Oscar B Goodman ,
Cora N Sternberg ,
Jin Hui Li ,
Thian Kheoh ,
Christopher M Haqq ,
Johann S de Bono
Oct 2012
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled phase 3 study. Here, we present the final analysis of the study before crossover from placebo to abiraterone acetate (after 775 of the prespecified 797 death events).